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Vasoinhibins are prolactin fragments present in the retina, where they have been shown
to prevent the hypervasopermeability associated with diabetes. Enhanced bradykinin
(BK) production contributes to the increased transport through the blood-retina barrier
(BRB) in diabetes. Here, we studied if vasoinhibins regulate BRB permeability by
targeting the vascular endothelium and retinal pigment epithelium (RPE) components
of this barrier. Intravitreal injection of BK in male rats increased BRB permeability.
Vasoinhibins prevented this effect, as did the B2 receptor antagonist Hoe-140. BK
induced a transient decrease in mouse retinal and brain capillary endothelial monolayer
resistance that was blocked by vasoinhibins. Both vasoinhibins and the nitric oxide (NO)
synthase inhibitor L-NAME, but not the antioxidant N-acetyl cysteine (NAC), blocked the
transient decrease in bovine umbilical vein endothelial cell (BUVEC) monolayer resistance
induced by BK; this block was reversed by the NO donor DETANONOate. Vasoinhibins
also prevented the BK-induced actin cytoskeleton redistribution, as did L-NAME. BK
transiently decreased human RPE (ARPE-19) cell monolayer resistance, and this effect
was blocked by vasoinhibins, L-NAME, and NAC. DETANONOate reverted the blocking
effect of vasoinhibins. Similar to BK, the radical initiator Luperox induced a reduction
in ARPE-19 cell monolayer resistance, which was prevented by vasoinhibins. These
effects on RPE resistance coincided with actin cytoskeleton redistribution. Intravitreal
injection of vasoinhibins reduced the levels of reactive oxygen species (ROS) in retinas of
streptozotocin-induced diabetic rats, particularly in the RPE and capillary-containing layers.
Thus, vasoinhibins reduce BRB permeability by targeting both its main inner and outer
components through NO- and ROS-dependent pathways, offering potential treatment
strategies against diabetic retinopathies.
Keywords: vasoinhibins, 16K prolactin, blood-retina barrier, retinal pigment epithelium, nitric oxide, reactive
oxygen species, oxidative stress, diabetes
INTRODUCTION
The functional integrity of the blood-retinal barrier (BRB) is
crucial for proper vision. The BRB consists of inner and outer
components that are mainly formed by vascular endothelial and
retinal pigment epithelial (RPE) cells, respectively (Klaassen et al.,
2013). Diverse conditions, including aging and diabetes, are asso-
ciated with excessive transport through the BRB (Gardner et al.,
2002; Klaassen et al., 2013). In this respect, increased levels
of bradykinin (BK), a hypotensive peptide that belongs to the
kinin-kallikrein system (Leeb-Lundberg et al., 2005), have been
detected in the vitreous of patients with diabetic retinopathy (Gao
et al., 2007), and the intravitreal injection of both BK and the
enzyme that produces BK from high molecular weight kininogen
(prekallikrein) induce excessive permeability through the BRB
causing edema in rats (Phipps et al., 2009; Clermont et al., 2011).
In addition, kinin receptor antagonists prevent the increase in
retinal vascular permeability due to diabetes in rats (Abdouh
et al., 2008).
Kinin receptors occur in two isoforms: the B2 receptor, which
is ubiquitously and constitutively expressed (Sainz et al., 2007),
and the B1 receptor, which is minimally expressed under phys-
iological conditions but up-regulated during tissue injury and
inflammation (Marceau and Regoli, 2004; Leeb-Lundberg et al.,
2005). BK binds preferentially to the B2 receptor (Charest-Morin
et al., 2014), which has been detected in the human retina (Takeda
et al., 1999). In rodents, there is functional evidence of its pres-
ence in retinal capillary endothelial (Abdouh et al., 2003) and
RPE (Ma et al., 1996; Lim et al., 2008, 2009) cells. Stimulation
of the B2 receptor has been shown to promote vascular per-
meability in endothelial cells of the blood-brain barrier (Revest
et al., 1991; Doctrow et al., 1994; Easton and Abbott, 2002; Raslan
et al., 2010) by increasing the production of both nitric oxide
(NO) via Ca2+/CaM kinase II activation (Cai et al., 2008) and
of reactive oxygen species (ROS) via arachidonic acid (Easton
and Abbott, 2002) and NADPH oxidase activation (Fischer et al.,
2005). Both NO and ROS cause cytoskeleton reorganization and
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subsequent tight and adherens junction reorganization (De Bock
et al., 2013) that, together, control endothelial cell permeability.
On the other hand, NO is known to contribute to the integrity
of RPE tight junctions (Zech et al., 1998), and increased ROS
production correlates with increased permeability through RPE
(Miura and Roider, 2009; Qin and Rodrigues, 2010; Kim et al.,
2012).
A major feature of aging- and diabetes-related retinopathies
is the excessive production of NO and ROS (Zheng and Kern,
2009). Therefore, more insight into the action mechanisms of
molecules that can modulate the BK pathway will contribute to
retinal health. Vasoinhibins, a family of peptides originating from
the proteolysis of the hormone prolactin (Clapp et al., 2006),
have been demonstrated to antagonize several effects of BK,
including vasorelaxation, vascular production of NO (Gonzalez
et al., 2004), and endothelial cell proliferation (Thebault, 2011).
Moreover, vasoinhibins prevent the excessive vasopermeability
associated with diabetes (Garcia et al., 2008). In this study,
we investigated whether vasoinhibins reduce the BK-induced
increase in BRB permeability by targeting both the endothelial
and the RPE components of this barrier. We also wished to ascer-
tain whether NO and ROS mediate these effects. To this end, we
quantified transport through the BRB using the Evans blue dye
method in rats, and we used monolayers of freshly isolated mouse
retinal and brain capillary endothelial cells, BUVEC and ARPE-19
to assess trans-electrical resistance (TER). We also analyzed the
filamentous (F-) actin distribution and contribution of the kinin
B2 and B1 receptors, NO, and ROS to the mechanism of vasoin-
hibin action using selective pharmacological agonists and/or
inhibitors. Our data support the hypothesis that vasoinhibins reg-
ulate endothelial and RPE cell permeability; furthermore, they
showed that vasoinhibins attenuate diabetes-related oxidative
stress in the retina, and that NO and ROS differentially contribute
to the regulation of permeability through endothelial and RPE cell
monolayers.
MATERIALS AND METHODS
REAGENTS
The vasoinhibins used in in vivo experiments corresponding to
the 16 kDa fragment were generated by the enzymatic cleavage
of rat prolactin from mammary gland extracts as previously
described (Clapp et al., 1993). Recombinant human vasoinhibins
(corresponding to a 14-kDa fragment of prolactin) used in cell
culture experiments were generated by site-directed mutagenesis
as previously described (Galfione et al., 2003). Other compounds
including BK, Nω-Nitro-L-arginine methyl ester hydrochlo-
ride (L-NAME), (Z)-1-[2-(2-aminoethyl)-N-(2-ammonio-
ethyl)amino]diazen-1-ium-1,2-diolate (DETANONOate),
N-acetylcysteine (NAC), Luperox (tert-butyl peroxide), the
kinin B2 receptor antagonist Hoe-140, and the Evans blue dye
were purchased from Sigma-Aldrich (St. Louis, MO), and the
5,59,6,69-tetrachloro-1,19,3,39 tetraethylbenzimidazolylcarbo-
cyanine iodide JC-1 dye was from Molecular probes (Eugene,
OR). The monoclonal anti-kinin B2 receptor, the polyclonal
anti-kinin B1 receptor, and polyclonal anti-β-tubulin antibodies
were purchased from BD Biosciences (610451), Santa Cruz
Biotechnology (sc-15048), and ZYMED (22833), respectively.
Secondary antibodies conjugated to alkaline phosphatase
(Bio-Rad Laboratories, Hercules, CA) were used.
ETHICS STATEMENT
All experiments were approved by the Bioethics Committee of the
Institute of Neurobiology (INEU/SA/CB/074) from the National
University of Mexico (UNAM, clave NOM-062-ZOO-1999) in
accordance with the rules and regulation of the Society for
Neuroscience: Policies on the Use of Animals and Humans in
Neuroscience Research. All efforts were made to minimize the
number of animals used and their suffering.
ANIMALS
Male albino rats (Wistar, 250–350 g) were fed ad libitum and
reared in normal cyclic light conditions (12h light: 12h dark).
A group of rats received L-NAME (1.8mM) in drinking water
for 15 days. Sprague-Dawley rats were immunized with Complex
Freund’s Adjuvant (Adan et al., 2013). For all procedures,
rats were anesthetized with ketamine/xylazine (7/3). Additional
anesthesia was provided throughout the procedures as needed.
Diabetes was induced with a single intraperitoneal injection of
streptozotocin (60mg/kg) in Wistar rats (Garcia et al., 2008), and
animals with glucose levels greater than 250mg/dl were used 4
weeks after diabetes induction.
CELLS
BUVEC (Cajero-Juarez et al., 2002) were grown in F12K culture
medium supplemented with 10% fetal bovine serum, 50U/ml
penicillin/streptomycin, and 1% fungizone (Life Technologies,
Grand Island, NY). The ARPE-19 human cell line (ATCC
Number: CRL-2302) (Dunn et al., 1996) was grown in Dulbecco’s
Modified Eagle’s Medium nutrient mixture F12 supplemented
with 1% fetal bovine serum. Cell cultures were cultured at
an initial density of 106 cells and maintained at 37◦C and
5% CO2.
PRIMARY CULTURES OF MOUSE BRAIN (MBCEC) AND RETINAL
(MRCEC) CAPILLARY ENDOTHELIAL CELLS
We isolated MBCEC and MRCEC from the mouse brain and
retina using collagenase digestion and magnetic-activated cell
sorting (MACS), ensuring a preparation of >90% purity. Briefly,
brains (devoid of cerebellum) and retinas from five to twenty
Cd-1 mice (4 weeks of age) were aseptically collected and rinsed
in Hank’s Balanced Salt Solution (GIBCO BRL, New York, NY)
supplemented with 1% bovine serum albumin (BSA) and 1%
penicillin/streptomycin, and were cut into small pieces. Tissue
was digested with 0.1% collagenase type 1 for 45min at 37◦C
under agitation (350 rpm). The cell-suspension was then filtered
through 70-micron mesh and centrifuged at 1200 rpm for 10min
at 4◦C. Supernatant from the brain-derived suspension was dis-
carded, and the pellet was treated with 2mL of erythrocyte lysis
buffer for 5min and centrifuged. Finally, CD31-positive cells
from both brain and retinal populations were isolated by MACS
as previously described (Smith et al., 2014).
INTRAVITREAL INJECTIONS
Rats were injected intravitreously as reported (Aranda et al.,
2005). The final injection volume was 5μl. One eye was injected
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with BK (60 pg per eye, corresponding to 1 nM as the estimated
volume of rat vitreous is 60μl, Guo et al., 2007) and the contra-
lateral eye with BK combined with vasoinhibins (1μg, 1μM) or
with the kinin B2 receptor antagonist Hoe-140 (235 ng, 3μM).
The control groups consisted of rat eyes injected with vehicle
(PBS), and the contralateral eye received vasoinhibins (1μM) or
Hoe-140 (3μM).
QUANTIFICATION OF BRB PERMEABILITY
The Evans blue dye permeation assay was performed as previ-
ously described (Xu et al., 2001; Garcia et al., 2008). It is however
worth mentioning that Evans blue dye was administered 2 h
after intravitreous injections, and left circulation for 2 additional
hours.
REAL-TIME PCR
RNA was isolated and cDNA synthesized from a 1-μg sample
as previously described (Arnold et al., 2014). Primer sequences
are documented in Table 1, and the conditions used for the
PCR reactions were as previously described (Arnold et al.,
2014). Cycle thresholds normalized to the housekeeping gene
hypoxanthine-guanine phosphoribosyltransferase (HPRT) were
used to calculate the mRNA levels of interest.
WESTERN-BLOT
Rat retinas and knees were homogenized in 0.5% Nonidet P-40,
0.1% SDS, 50mM Tris, 150mM NaCl, 1mM phenylmethylsul-
nonyl fluoride, and 1mM aprotinin (pH 7) and centrifuged
(10,000 g for 10min). Supernatant proteins (40μg) were resolved
by 7.5 or 10% SDS-polyacrylamide gels under reducing condi-
tions, transferred to nitrocellulose membranes, and probed with
an anti-kinin B2 or B1 receptor (1:500 and 1:50 dilution, respec-
tively) and anti-β-tubulin (1:1000 dilution) antibodies. Primary
antibodies were revealed using secondary antibodies conjugated
to alkaline phosphatase. Optical density values were deter-
mined using the Quantity One, 1-D analysis software (Bio-Rad,
Hercules, CA).
F-ACTIN STAINING
Cells were grown on matrigel-coated coverslips until confluence.
After treatment, cells were fixed with 4% paraformaldehyde for
10min at room temperature. Then cells were washed twice with
PBS and permeabilized with 0.1% Triton X-100 in PBS for 5min.
Changes in F-actin structures were detected by incubating the
cells for 20min at room temperature with a 1:100 dilution of
TRITC-labeled phalloidin (Molecular Probes). Coverslips were
then washed twice with PBS and mounted in VECTASHIELD®
Table 1 | Details of primer sequences.
mRNA NCBI Forward Reverse Primer
accession
number
sequence sequence efficiency
(%)
Hprt NM_012583.2 TTGCTGACCT
GCTGGATTAC
GTTGAGAGATCA
TCTCCACC
100.8
B2R NM_173100.2 CCCTTCCTCT
GGGTCCTCTT
CAGAACACGCT
GAGGACAAAGA
93.5
mounting medium with DAPI. Images were obtained using a
LSM 510 confocal laser scanning microscope (Carl Zeiss, Jena,
Germany).
MEASUREMENT OF TER
BUVEC, MRCEC, MBCEC, and ARPE-19 cells were grown on
1.12-cm2 Transwell clear polyester membrane inserts (Corning
Inc., Corning, NY) with pore sizes of 8.0μm for BUVEC and
0.4μm for other cells, and monitored until stabilization of TER
(average of 180 to 200 .cm2) using the EVOM2 Epithelial
Voltohmmeter (World Precision Instrument). TERwas thenmea-
sured over a 90-min period from each insert unless another
time period is specified. TER values were expressed as percent of
control (complete medium) at time 0.
ASSESSMENT OF MITOCHONDRIAL ROS PRODUCTION USING JC-1
DYE
Hyperpolarization of the mitochondrial membrane potential
results in increased ROS generation (Teshima et al., 2014). The
JC-1 dye is freely permeable to cells and undergoes reversible
transformation from a monomer (emitting at ∼530 nm (green)
in response to a 535-nm excitation) to an aggregate form (emit-
ting red fluorescence at ∼590 nm (red) in response to a 485-nm
excitation) when it binds to hyperpolarized mitochondrial mem-
branes (Cossarizza et al., 1993). A decrease in the aggregate
fluorescence (red; 590) is indicative of depolarization, whereas an
increase indicates hyperpolarization. BUVEC (1 × 105 cells/well)
and ARPE-19 (1.5 × 105 cells/well) cells in 96-well plates were
treated as indicated in Figures 4E, 6D diagrams. The cells were
then washed and incubated in the dark with 10μg/mL JC-1 dye
at 37◦C for 10min. The mitochondrial membrane potential was
measured using a bioplate reader (Victor3 V [Perkin Elmer];
green fluorescence, 530 nm; red fluorescence, 570 nm).
MEASUREMENT OF SUPEROXIDE USING THE VICTOR3 V MICROPLATE
READER
Superoxide levels were monitored according to the
Manufacturer’s instructions (The Enzo Life Sciences’ Total
ROS/Superoxide detection kit; ENZ-51010).
FLUORESCENT DETECTION OF INTRACELLULAR ROS
The in vivo production of ROS in the retina was assessed using
dihydroethidium (DHE) staining. First, eyes were fixed in 4%
PFA for 4 h and then placed in 15 % sucrose for 1 day. Eyes
were frozen (Tissue-Tek; Sakura Finetek, Torrance, CA), and 20-
μm cryostat sections were mounted on gelatin-coated slides. In
a dark chamber, retinal sections were loaded with 5μM DHE
for 30min at room temperature and then washed thrice in PBS.
Sections were mounted on glass slides with VECTASHIELD®
mounting medium with DAPI, and the slides were analyzed with-
out delay using a LSM 510 confocal laser-scanning microscope.
Images were obtained using an Apo-406 objective. The same
acquisition settings were used for all experiments to allow direct
comparison of retinal explants. Digital images were processed
using free ImageJ software (Rasband, W.S., ImageJ; U.S. NIH,
Bethesda). Only cropping of images was performed; there was no
adjustment of brightness. The mean fluorescence intensity ratio
of each retinal layer was determined in 6 different regions of
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FIGURE 1 | Vasoinhibins prevent BK-induced increase in BRB
permeability similarly to a kinin B2 receptor antagonist. (A) Evaluation of
the Evans blue dye content in retinas of rats intravitreously injected 4 h earlier
with PBS (Ctl), BK (1 nM), BK combined with either vasoinhibins (Vi, 1μM) or
Hoe-140 (Hoe, 3μM), Vi alone, or Hoe alone. Values are mean ± s.e.m.
normalized to the control (n = 8–16 per group; ∗P < 0.05). (B–D) Retinas of
rats that were intravitreously injected 4 h earlier with PBS, BK, Vi, or BK
combined with Vi were analyzed for kinin B2 receptor mRNA (B, mean ±
s.e.m. from 5 independent experiments) and protein (C). Total β-tubulin
served as loading control. (D) Quantification of kinin B2 receptor by
densitometry normalized to total β-tubulin. Values correspond to the mean ±
s.e.m. from 3 independent experiments. (E) Retinas of rats that were
intravitreously injected 4 h earlier with PBS, BK, Vi, or BK combined with Vi
were analyzed for kinin B1 receptor protein. Total knee extract from rats with
Freund’s adjuvant-induced arthritis (AT, arthritic tissue) was used as a positive
control for B1 receptor expression. NS, not significant.
interest (same size), distributed equally over the full layer, from
one retinal section per time point (each of which was represen-
tative of 3 experiments). The ratio between PBS (numerator)
and vasoinhibins, time-matched control retinas was calculated by
2 single-blind, independent observers to determine superoxide
anion production in specific treatment groups.
STATISTICAL ANALYSIS
All results were replicated in three or more independent
experiments. Data were presented as mean ± s.e.m.; all
data showed normal distribution or equal variance accord-
ing to Kolmogorov-Smirnov and Levene’s tests, respectively.
Statistical differences among groups were determined by One-
Way ANOVA followed by Bonferroni’s post-hoc comparison
test (Sigma Stat 7.0, Systat Software Inc., San Jose, CA).
Differences in means with P < 0.05 were considered statistically
significant.
RESULTS
VASOINHIBINS PREVENT BK-INDUCED INCREASE IN BRB
PERMEABILITY SIMILARLY TO A KININ B2 RECEPTOR ANTAGONIST
The intravitreal injection of BK induced a 1.8-fold increase in the
basal transport through the BRB compared to the PBS-injected
eyes (Ctl) (Figure 1A). When coinjected with BK, vasoinhibins
prevented the BK-induced increase in BRB permeability in aman-
ner similar to that of the competitive kinin B2 receptor antagonist
Hoe-140 (Figure 1A). Alone, vasoinhibins or Hoe-140 did not
modify the transport through the BRB. Signaling through the
kinin B2 receptor has been shown to be primarily controlled by
short-term mechanisms including both receptor desensitization
(Mathis et al., 1996) and internalization (Munoz and Leeb-
Lundberg, 1992; Munoz et al., 1993), but it can also be regulated
by changes in expression levels of the receptor (Nostramo et al.,
2013). Thus, retinas of animals that were intravitreally injected
with BK, vasoinhibins, or both were analyzed for B2 receptor
mRNA and protein levels by real-time PCR and Western-blot,
Frontiers in Cellular Neuroscience www.frontiersin.org October 2014 | Volume 8 | Article 333 | 4
Arredondo Zamarripa et al. Vasoinhibins regulate blood-retinal barrier
FIGURE 2 | Vasoinhibins block BK-induced reduction of
transendothelial resistance and morphological changes in actin
cytoskeleton. Time course of trans-electrical resistance (TER) in MRCEC
(A) and MBCEC (B) monolayers cultured in complete medium (Ctl) with or
without 10μM BK and 10nM vasoinhibins (Vi). (C) TER in BUVEC
monolayers cultured in complete medium (Ctl) with or without 10μM BK
and 10nM Vi. (D) Expanded early time values of experiment (C). In (A–D),
values are mean ± s.e.m. from 3 independent experiments normalized to
the control; ∗P < 0.05 vs. Ctl. MBCEC and MRCEC were cultured on
inserts with pore sizes of 0.4μm while BUVEC cells were cultured on
inserts with pore sizes of 8.0μm. (E) BUVEC were cultured in complete
medium (Ctl) with or without 10μM BK and 10nM Vi for 15min and then
actin cytoskeleton (F-actin) distribution was determined using
rhodamine-phalloidin. Representative fields are shown. Scale bar, 10μm.
respectively. The retinal levels of B2 receptor mRNA (Figure 1B)
and protein (Figure 1C) were not different between PBS-, BK-,
Vi-, and (BK + Vi)-injected eyes. Figure 1D shows quantification
of B2 receptor after normalization for the amount of β-tubulin
on the gel. Treatment with BK has been shown to induce the
kinin B1 receptor (Phagoo et al., 1999). However, in addition to
being absent in rat retina under physiological conditions, the B1
receptor is also absent after BK injection, combined or not with
vasoinhibins (Figure 1E). Total knee extract from rats subjected
to the adjuvant model of inflammatory arthritis for 21 days (Adan
et al., 2013) was used as a positive control for B1 receptor expres-
sion. Notably, the band detected in arthritic tissue (AT) with
the polyclonal anti-B1 receptor antibody migrates at an apparent
molecular weight of 35 kDa, the molecular mass of the B1 recep-
tor (see http://datasheets.scbt.com/sc-15048.pdf), thus validating
the efficacy of the Western blot detection. These data indicate
that vasoinhibins mitigate the BK-mediated increase in BRB per-
meability, that this results from kinin B2, but not B1, receptor
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FIGURE 3 | The inhibitory effect of vasoinhibins on BK-induced reduction
of transendothelial resistance and actin cytoskeleton rearrangement
depends on NO. (A) Time course of TER in BUVEC monolayers cultured in
complete medium (Ctl) with or without 10μM BK and the NO synthase
inhibitor L-NAME (10mM). Values are mean ± s.e.m. from 3 independent
experiments normalized to the control. ∗P < 0.05 vs. Ctl. (B) Rats were
treated with L-NAME (1.8mM) administered in the drinking water for 15 days,
then their retinas were intravitreously injected with PBS (Ctl) or BK (1 nM),
and evaluated 2 h later by the Evans blue dye assay. Values are mean ± s.e.m.
normalized to control. ∗P < 0.05 from 8 to 16 independent observations.
(C) Quantification of peak TER values (15min after treatment start) in BUVEC
monolayers cultured in complete medium (Ctl) with or without 10μM BK and
10nM Vi in the absence (white bars) or presence (black bars) of the NO donor
DETANONOate (10μM). ∗P < 0.05 from 3 independent experiments. NS, not
significant. BUVEC were cultured on inserts with pore sizes of 8.0μm.
(D) BUVEC were cultured in complete medium (Ctl) with or without 10μM
BK and 10mM L-NAME, and with the NO donor DETANONOate (10μM) in
the presence and in the absence of BK and Vi (10 nM) for 15min, and then
actin cytoskeleton (F-actin) distribution was determined using
rhodamine-phalloidin. Representative fields are shown. Scale bar, 10μm.
activation, and that vasoinhibins do not change the amount of B2
receptor.
VASOINHIBINS BLOCK THE REDUCTION OF TRANS-ELECTRICAL
RESISTANCE (TER) INDUCED BY BK IN MRCEC, MBCEC, AND BUVEC
MONOLAYERS
The inner BRB refers to the layer of capillaries in the inner
retina with very low permeability, due to the interactions between
vascular endothelial cells and surrounding cells (pericytes and
macroglia) (Klaassen et al., 2013). Freshly isolated mouse reti-
nal (Figure 2A) and brain (Figure 2B) capillary endothelial cells
showed stable resistance over time. BK induced a transient
decrease in TER that was maximal at 15min and was fully pre-
vented by vasoinhibins (Figures 2A,B). Vasoinhibins alone had
no effect (Figures 2A,B). Monolayers of BUVEC that express B2
receptors (Wohlfart et al., 1997), also showed stable resistance
over time (Figure 2C). BK induced a transient decrease in TER
that was maximal at 10min (Figures 2C,D) and was fully pre-
vented by vasoinhibins (Figure 2C). Vasoinhibins alone had no
effect (Figure 2C). The cytoskeleton is composed of actin micro-
filaments, which are critical for endothelial cell permeability
(Dudek and Garcia, 2001). Treatment with BK induced F-actin
redistribution and stress fiber formation in BUVEC (Figure 2E).
These effects were blocked by vasoinhibins, and vasoinhibins had
no effect alone (Figure 2E).
VASOINHIBINS BLOCK THE BK-INDUCED DECREASE IN BUVEC
RESISTANCE AND ACTIN CYTOSKELETON REDISTRIBUTION BY
ACTING UPSTREAM OF NO PRODUCTION
We observed that coadministration of the NOS inhibitor L-
NAME (Rees et al., 1989) eliminated the BK-induced decrease
in TER, but L-NAME alone had no effect (Figure 3A).
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FIGURE 4 | ROS do not participate in the vasoinhibin-mediated
inhibition of transendothelial resistance reduction and actin
cytoskeleton rearrangement induced by BK. (A,C) Time course of
trans-electrical resistance (TER) in BUVEC monolayers cultured in
complete medium (Ctl) with or without 10μM BK and the antioxidant
N-acetyl cysteine (NAC, 10mM) or with or without 500μM Luperox and
vasoinhibins (Vi, 10 nM). BUVEC were cultured on inserts with pore sizes
of 8.0μm. (B) Corresponding quantification of TER values, 10min after
treatment initiation. Values correspond to the mean ± s.e.m. from 3
independent experiments. ∗P < 0.05. NS, not significant. (D) BUVEC
were cultured in complete medium (Ctl) with or without 10μM BK and
10mM NAC or with or without 500μM Luperox and Vi (10 nM) for
15min, and then actin cytoskeleton (F-actin) distribution was determined
using rhodamine-phalloidin. Representative fields are shown. Scale bar,
10μm. (E) Mitochondrial membrane potential changes using JC-1 dye in
BUVEC monolayers cultured in complete medium (Ctl) with or without
10μM BK or 500μM Luperox and 10 nM Vi. Values correspond to the
mean ± s.e.m. from 3 independent experiments. ∗P < 0.05. NS, not
significant. (F) Cytosolic levels of superoxide in BUVEC monolayers
cultured in complete medium (Ctl) with or without 10μM BK. Values
correspond to the mean ± s.e.m. of 8 repeats per condition from 3
independent experiments.
Administration of L-NAME (1.8mM) in the rats’ drink-
ing water for 15 days also counteracted BK action on BRB
permeability (Figure 3B), mimicking the vasoinhibin effect
(Figure 1A). In support of NO being essential for BK effects,
the NO donor DETANONOate mimicked the BK effect on
TER, and coadministration of DETANONOate did not enhance
BK action (Figure 3C). We then asked whether the NO
donor DETANONOate reverts the action of vasoinhibins in
the presence of BK. Exogenous NO prevented vasoinhibin-
mediated inhibition of BK-induced reduction of TER in BUVEC
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FIGURE 5 | BK transiently reduces ARPE-19 cell monolayer resistance
and induces actin cytoskeleton rearrangement through NO, and
vasoinhibins prevent these effects. (A,B) Time course of
trans-electrical resistance (TER) in ARPE-19 monolayers cultured in
complete medium (Ctl) with or without 10μM BK and vasoinhibins (Vi,
10 nM) or L-NAME (10mM). Values correspond to the mean ± s.e.m.
from 3 independent experiments. ∗P < 0.05 vs. Ctl. (C) Quantification
of peak TER values (15min after treatment start) in ARPE-19
monolayers cultured in complete medium (Ctl) with or without 10μM
BK and 10 nM Vi in the absence (white bars) or presence (black bars)
of the NO donor DETANONOate (10μM). ∗P < 0.05 from 3
independent experiments. NS, not significant. ARPE-19 cells were
cultured on inserts with pore sizes of 0.4μm. (D) ARPE-19 cells were
cultured in complete medium (Ctl) with or without 10μM BK and
vasoinhibins (Vi, 10 nM) or L-NAME (10mM) or the NO donor
DETANONOate (10μM) for 15min, and then actin cytoskeleton (F-actin)
distribution was determined using rhodamine-phalloidin. Representative
fields are shown. Scale bar, 10μm.
(Figure 3C). In addition, L-NAME prevented BK-induced redis-
tribution of F-actin and stress fiber formation, but had no
effect alone (Figure 3D). Also, DETANONOate induced F-actin
redistribution and stress fiber formation similarly to BK, and
coadministration of DETANONOate did not enhance BK action
(Figure 3D). In this context, vasoinhibins were not able to block
DETANONOate-induced F-actin rearrangement, and exogenous
NO prevented vasoinhibin-mediated inhibition of BK-induced
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FIGURE 6 | ROS contribute to the inhibition of BK-induced decrease of
ARPE-19 resistance and actin cytoskeleton rearrangement by
vasoinhibins. (A,B) Time course of trans-electrical resistance (TER) in
ARPE-19 monolayers cultured in complete medium (Ctl) with or without
10μM BK and N-acetyl cysteine (NAC, 10mM) or with or without 500μM
Luperox and vasoinhibins (Vi, 10 nM). Values correspond to the mean ±
s.e.m. from 3 independent experiments. ∗P < 0.05 vs. Ctl. ARPE-19 cells
were cultured on inserts with pore sizes of 0.4μm. (C) ARPE-19 cells were
cultured in complete medium (Ctl) with or without 10μM BK and NAC
(10mM) or with or without 500μM Luperox and Vi (10 nM) for 15min, and
then actin cytoskeleton (F-actin) distribution was determined using
rhodamine-phalloidin. Representative fields are shown. Scale bar, 10μm.
(D) Mitochondrial membrane potential changes using JC-1 dye in ARPE-19
monolayers cultured in complete medium (Ctl) with or without 10μM BK or
500μM Luperox and Vi (10 nM). Values correspond to the mean ± s.e.m.
from 3 independent experiments. (E) Cytosolic levels of superoxide in
ARPE-19 monolayers cultured in complete medium (Ctl) with or without
10μM BK and NAC (10mM) or with or without 10μM BK and Vi (10 nM).
Values correspond to the mean ± s.e.m. of 4–15 repeats per condition from 3
independent experiments. ∗P < 0.05 vs. Ctl. NS, not significant.
F-actin redistribution in BUVEC (Figure 3D). All together, these
data show that NOmediates the BK-induced increase in endothe-
lial cell monolayer permeability and actin cytoskeleton redistribu-
tion, and that vasoinhibins block these actions by acting upstream
of NO production, as previously reported (Gonzalez et al., 2004;
Thebault, 2011).
THE VASOINHIBIN-MEDIATED INHIBITION OF TER REDUCTION AND
ACTIN CYTOSKELETON REDISTRIBUTION INDUCED BY BK IS
INDEPENDENT OF INTRACELLULAR ROS PRODUCTION
Evidence suggests that increased retinal vascular permeability
in response to agonists such as BK is associated with increased
ROS load (Wohlfart et al., 1997; Fong et al., 2010), which
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can be reduced inside the cell by free radical scavengers like
NAC (Zavodnik et al., 2013). We observed that NAC did not
block BK-induced reduction of TER in BUVEC (Figure 4A).
Figure 4B shows the quantification of TER values at 15min, when
the BK effect was maximal. On the other hand, the free rad-
ical initiator Luperox (Zavodnik et al., 2013) did reduce TER
in BUVEC after 30min, an effect that persisted throughout
the 90-min recording period (Figure 4C). Vasoinhibins delayed
the action of Luperox by 15min, without affecting the mag-
nitude of its effect (Figure 4C). Furthermore, the BK-induced
F-actin redistribution and stress fiber formation was not pre-
vented by the antioxidant NAC, and NAC alone had no effect
(Figure 4D). Luperox did not significantly affect F-actin dis-
tribution, nor did it when co-administered with vasoinhibins
(Figure 4D). Further, we assessed the levels of ROS generated by
mitochondrial oxidative phosphorylation, using the JC-1 probe.
Levels of ROS were assessed in BUVEC monolayers treated with
BK for 15min, when its decrease of TER is maximal. BK did
not modify intracellular ROS levels compared with untreated
BUVEC monolayers (Figure 4E). A 15- and 45-min exposure
of BUVEC to Luperox decreased the 530/590 optical density
ratio, indicating increased levels of intracellular ROS (Figure 4E).
Concomittant administration of vasoinhibins did not prevent
the Luperox-induced production of ROS. While ROS levels were
not modified after a 15-min incubation with vasoinhibins alone,
they were reduced when the incubation with vasoinhibins was
extended to 45min (Figure 4E). In addition, ROS can be gen-
erated from oxidoreductase enzymes and metal-catalyzed oxida-
tion. However, BK did not modify cytosolic levels of superoxide
in BUVEC (Figure 4F). The observations that BK and Luperox
acted with different kinetics, that NAC did not block the BK
effect, and that BK does not modify the levels of ROS gener-
ated as byproducts during mitochondrial electron transport or
as intermediates of metal-catalyzed oxidation reactions, indicate
that ROS do not contribute to BK action. Our data also show
that vasoinhibins delay the ROS effect on transendothelial resis-
tance and that the vasoinhibins per se reduce the intraendothelial
levels of ROS.
BK INDUCES A TRANSIENT REDUCTION OF ARPE-19 CELL MONOLAYER
RESISTANCE AND AN ACTIN CYTOSKELETON REDISTRIBUTION THAT
INVOLVE NO, AND VASOINHIBINS PREVENT THESE EFFECTS
We then tested if vasoinhibins also target the RPE component of
BRB using the ARPE-19 cell line that expresses the B2 receptor
(Yasuyoshi et al., 2000; Lim et al., 2008). In control conditions,
the ARPE-19 monolayers showed stable resistance over time
(Figure 5A). BK induced a transient decrease in TER of ARPE-19
monolayers; this reduction was similar in magnitude (15 ± 1 vs.
9 ± 2 %) and time-course (maximum at 10–15min) to the one
observed in BUVEC monolayers. Vasoinhibins prevented the
BK-induced decrease in ARPE-19 monolayer resistance, but they
had no effect alone (Figure 5A). Similarly, blocking NO pro-
duction with L-NAME abrogated the action of BK (Figure 5B).
Addition of exogenous NO (DETANONOate) reduced TER in
ARPE-19 monolayers, mimicking the BK effect, and it prevented
vasoinhibins from blocking the BK-induced reduction of TER
(Figure 5C). Concomittantly, treatment with BK induced F-actin
redistribution in ARPE-19, an effect that was blocked by vasoin-
hibins (Figure 5D), which had no effect alone (Figure 5D).
L-NAME prevented BK-induced F-actin redistribution and had
no effect alone (Figure 5D). The NO donor DETANONOate
also promoted F-actin redistribution; co-administration of BK
and DETANONOate did not further promote F-actin rear-
rangement but in the presence of BK and DETANONOate,
vasoinhibins did not inhibit the F-actin redistribution
(Figure 5D).
INTRACELLULAR ROS CONTRIBUTE TO THE INHIBITION OF
BK-INDUCED DECREASE OF ARPE-19 RESISTANCE AND ACTIN
CYTOSKELETON REDISTRIBUTION BY VASOINHIBINS
The antioxidant NAC blocked BK-induced reduction of TER
in ARPE-19 (Figure 6A), but alone, NAC had no effect. Also,
Luperox induced a transient decrease in TER that was prevented
by vasoinhibins (Figure 6B). Both the magnitude (15 ± 1 vs.
9 ± 2%) and kinetics (maximum at 10 vs. 15min) of the Luperox
effect were similar to those of BK. NAC had no effect alone
but blocked the BK-induced F-actin redistribution (Figure 6C).
Similarly to BK, Luperox induced F-actin redistribution, an effect
that was inhibited by vasoinhibins (Figure 6C). Intracellular lev-
els of ROS were assessed in the presence and absence of vasoin-
hibins with BK or Luperox for 15min, when their effects on TER
were maximal. BK did not modify ROS levels in ARPE-19, while
Luperox increased them (Figure 6D). Alone or combined with
BK or Luperox, vasoinhibins had no effect (Figure 6D). In con-
trast, BK increased cytosolic levels of superoxide in ARPE-19 at
15min, and both NAC and vasoinhibins blocked this increase
(Figure 6E).
VASOINHIBINS REDUCE THE LEVELS OF ROS IN THE RETINA OF
STREPTOZOTOCIN-INDUCED DIABETIC RATS
To assess the physiological relevance of our findings, we ana-
lyzed the production of superoxide anion in retinas of rats that
were rendered diabetic (Pouliot et al., 2012). Figure 7A shows
representative images of retinas stained with the oxidative flu-
orescent dye DHE (red) and the DNA stain DAPI (blue), and
quantification using the mean pixel fluorescence intensity ratio
of DHE/DAPI for each nuclear layer of the retina is provided
in Figure 7B. In all conditions, the outer segments of pho-
toreceptors were positive for DHE staining due to non-specific
autofluorescence (Ling-Ling Zhao et al., 2009). In non-diabetic
retinas, the RPE produced more superoxide anion than other
layers (shown with an arrow head). After 4 weeks of diabetes,
superoxide anion production was enhanced in the RPE (indicated
with arrow heads in micrograph), outer nuclear and ganglion
cell layers (indicated with asterisks in micrograph), as previously
reported (Pouliot et al., 2011). Intravitreal injection of vasoinhib-
ins abolished the diabetes effect on levels of superoxide anions
in the RPE and the three nuclear layers of the retina. Alone,
vasoinhibins had no effect on basal production of superoxide
anions in the retina.
DISCUSSION
BRB capillary endothelial and RPE cells exhibit regulated
transcytotic activity and a tight junctional network that, aided by
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FIGURE 7 | Vasoinhibins reduce the retinal levels of ROS in
streptozotocin-induced diabetic rats. (A) Representative images of
superoxide anion production stained with dihydroethidium (DHE) on retina
sections from control (Ctl) rats intravitreously injected with PBS or
vasoinhibins (Vi, 1μM) for 24 h and from streptozotocin (STZ)-induced
diabetic rats intravitreously injected with PBS or Vi 24 h before the end of the
4 weeks of diabetes. Scale bar is 100μm. (B) Fluorescence intensity of
superoxide anion quantified as mean number of pixels positive for DHE
staining normalized to the mean number of pixels positive for DAPI staining in
the retinal pigment epithelium (RPE), outer nuclear (ONL), inner nuclear (INL),
inner plexiform (IPL), and ganglion cell (GCL) layers. Data are mean ± s.e.m.
of values obtained from 3 rats in each group. ∗P < 0.05. NS, not significant.
the cytoskeleton, restricts paracellular permeability. Both trans-
and paracellular pathways are the subject of extensive research
as they relate to retinal degeneration, edema and inflammation.
Notably, increased permeability is a prominent feature of oxida-
tive insult to the retina. Vasoinhibins potently inhibit the increase
in retinal vasopermeability associated with diabetes (Garcia et al.,
2008), but their effect on the RPE component of the BRB and on
oxidant-related mechanisms in the retina is unknown. Here, we
show that vasoinhibins regulate BRB permeability by targeting
both endothelial and RPE cells, and by limiting excessive oxida-
tive stress in the diabetic retina. BK is an important disruptor
of the BRB in diabetes that can be counteracted by vasoinhibins.
BK alters not only the vascular but also the RPE compartment.
After confirming that NO mediates the BK-induced decrease in
endothelial monolayer resistance, we show for the first time that
ROS are not involved in this effect but that both NO and ROS
are involved in the BK reduction of RPE monolayer resistance.
Notably, vasoinhibins prevent BK actions in both endothelial and
RPE monolayers.
Consistent with previous studies (Abdouh et al., 2003), we
demonstrate that intravitreal injection of BK in rats stimulates
Evans blue dye permeation, indicating increased permeability of
the BRB. The dose of BK we used (10μM) promotes vasodila-
tion (Gonzalez et al., 2004), but given that BK binds to the B2
receptor with an EC50 of 2 nM (Gera et al., 2011), we assume
that this dose is pharmacological. Nonetheless, high levels of BK
may be found in the eye under conditions of diabetic retinopathy,
when the levels of carbonic anhydrase I, an enzyme responsi-
ble for generating BK (Han et al., 2002; Gao et al., 2007), are
∼15- and ∼8-times higher than in non-diabetic patients and
in patients with diabetes without retinopathy, respectively (Gao
et al., 2007). Additionally, vasoinhibins opposed the BK action at
concentrations previously demonstrated to prevent the vascular
hyperpermeability observed in diabetes (Garcia et al., 2008).
Earlier studies found that a B2 receptor antagonist reduces the
retinal plasma extravasation induced by BK (Abdouh et al., 2008).
Here, we show that Hoe-140, the competitive antagonist of B2
receptors, blocked the BK-induced increase in BRB transport, as
did vasoinhibins. Because B1 receptors were not detected in the
retina of rats subjected to BK treatment and because the competi-
tive B2 receptor antagonist Hoe-140 fully blocked the BK effect on
BRB permeability, we conclude that the BK-induced increase in
BRB transport depends on B2 receptor stimulation. Furthermore,
vasoinhibins have been shown to antagonize other B2 receptor-
mediated effects of BK (Gonzalez et al., 2004; Thebault, 2011), the
inhibition of phospholipase C activity being the most upstream
target reported for vasoinhibins in the BK signaling pathway
(Thebault, 2011). Given that changes in B2 receptor mRNA lev-
els have been detected immediately after stress exposure, leading
to changes in protein levels at 3 h (Nostramo et al., 2013), we
postulated that vasoinhibins could down-regulate B2 receptor
expression within the 2-h period during which we observed the
in vivo effect of BK. However, there were no changes in B2 recep-
tor mRNA and protein levels in the retina of rats subjected to BK
treatment with or without vasoinhibins. Consequently, we pro-
pose that vasoinhibins negatively regulate B2 receptor signaling
by short-term mechanisms that may include receptor desensi-
tization (Mathis et al., 1996) and internalization (Munoz and
Leeb-Lundberg, 1992; Munoz et al., 1993).
Stimulation of B2 receptors has been shown to evoke intracel-
lular Ca2+ mobilization in cultured retinal capillary endothelial
cells and to induce vascular permeability, vasodilation, and thick-
ening of the retina, substantiating that the intraocular kallikrein-
kinin system is functional in the retina (Abdouh et al., 2003).
However, the only known BK effects on retinal non-vascular
cells are to promote glutamate uptake by ARPE-19 cells (Lim
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et al., 2008) and to decrease retinal glutamate toxicity in cul-
tured retinal neurons (Yasuyoshi et al., 2000). Our data pro-
vide the first demonstration that BK transiently reduces the
trans-electrical resistance through ARPE-19 cell monolayers. This
action shares similarities in amplitude and kinetics with the BK
action on endothelial cell monolayers derived from freshly iso-
lated retinal and brain capillary endothelial cells, and also from
BUVEC, and it supports the role of BK as a direct regulator
of both the inner endothelial and outer RPE components of
the BRB. In addition to confirming that BK enhances trans-
port through the brain-blood barrier (Harford-Wright et al.,
2011), these findings extend BK actions to other blood-organ
barriers.
Activation of the B2 receptor stimulates the NO production
via Src/PI3kinase/Akt-dependent activation of eNOS (Bae et al.,
2003), which has been associated with alterations in endothelial
resistance and permeability (Pricci et al., 2003; Wilkinson-Berka,
2004; Frey and Antonetti, 2011). Our findings confirm that exoge-
nous NO reduces the electrical resistance through endothelial
monolayers and extend this effect of NO to the RPE. We also
found that pharmacological inhibition of NO production leads
to inhibition of the BK-induced increase of BRB transport and
of permeability through both endothelial and RPE monolayers.
Concerning the latter, even though constitutive NOS expres-
sion has not been described in ARPE-19 cells, RPE is positive
for NADPH-diaphorase, a marker of NOS activity (Goldstein
et al., 1996; Fischer and Stell, 1999). Our data also showed that
vasoinhibins block the transient decrease in BUVEC and ARPE-
19 monolayer resistance induced by BK, as did the NO synthase
inhibitor L-NAME. In addition, the NO donor DETANONOate
prevented vasoinhibins from blocking the BK effect in both
cell types, supporting that the vasoinhibin act by inhibiting
NO production, as previously demonstrated for endothelial cells
(Gonzalez et al., 2004). While this is the first evidence that
RPE cells respond to vasoinhibins, we previously demonstrated
that vasoinhibins block BK-induced endothelial NO production
by inactivating eNOS via two mechanisms: reduced intracellu-
lar Ca2+ mobilization (Gonzalez et al., 2004) and activation of
protein phosphatase 2A-induced dephosphorylation at serine1179
(Garcia et al., 2008; Thebault, 2011).
NO can also stimulate protein kinase G, which causes the
release of mitochondrial ROS into the cytosol (Oldenburg
et al., 2004), and BK induces oxidative stress through an
NO-independent mechanism in the human vasculature (Fong
et al., 2010). However, neither endothelial nor RPE cells showed
increased levels of ROS as byproducts during mitochondrial
electron transport in response to BK, which may be due to NO-
induced inhibition of ROS production (Kayashima et al., 2012).
Indeed, NO produced in response to BK (Gonzalez et al., 2004)
may impede ROS production by negatively regulating oxidative
phosphorylation through the inhibition of cytochrome c oxidase.
Also, BK did not modify the levels of superoxide formed as an
intermediate of metal-catalyzed oxidation reactions. Moreover,
we found that the radical initiator Luperox induced an increase
in endothelial cell permeability with longer latency and dura-
tion compared to the effect of BK, and that the antioxidant NAC
did not modify the increased permeability due to BK; thus, ROS
may not contribute to the BK-induced decrease in endothelial cell
resistance.
In contrast, our data indicate that ROS participate in the BK-
mediated regulation of RPE resistance. Luperox mimicked the
BK effect on ARPE-19 monolayer resistance in terms of ampli-
tude, kinetics and actin cytoskeleton rearrangement, coinciding
with the disruption of junctional proteins previously reported in
association with increased ROS (Miranda et al., 2012; Zavodnik
et al., 2013 and present data). BK per se caused superoxide anion,
but not ROS, to accumulate in ARPE-19 cells as a by-product
during mitochondrial electron transport. Consistent with these
data, the antioxidant NAC prevented the decrease in ARPE-19
monolayer resistance induced by BK. Moreover, our data show
that vasoinhibins mimicked the effect of NAC and prevented the
transient reduction of ARPE-19 resistance induced by Luperox,
indicating that vasohibins act by antagonizing ROS. Along this
line, the intravitreal injection of vasoinhibins in the diabetic rats
reduced the retinal levels of superoxide anion to control val-
ues. These data unveil vasoinhibins as potent anti-oxidants in
the diabetic retina. We observed that a 45-min treatment with
vasoinhibins diminished ROS levels in endothelial cells. Even
though the same in vitro assay showed that vasoinhibins did not
block the generation of ROS induced by Luperox, vasoinhibins
did inhibit the BK-induced increase of superoxide anion levels
in ARPE-19 cells, as did NAC. These findings support the idea
that inhibition of ROS production contributes to the vasoinhibin
inhibition of permeability. An additional mechanism may be that
vasoinhibins promote anti-oxidant mechanisms, thereby protect-
ing RPE against oxidant-mediated monolayer dysfunction (Ho
et al., 2006) and endothelial cells from oxidant-mediated per-
meability dysregulation (Yamagishi et al., 2006; Sheikpranbabu
et al., 2010; Kim et al., 2012) and damage (Banumathi et al.,
2010; Dou et al., 2012). The pigment epithelium-derived factor
(PEDF) acts in this way, and vasoinhibins may, therefore, share
some molecular actions with PEDF. Indeed, both vasoinhibins
and PEDF stabilize the actin cytoskeleton in both endothelial and
RPE cells. Also, vasoinhibins may preserve the reduced/oxidized
glutathione ratio (Miura and Roider, 2009) and maintain nor-
mal membrane occludin and N-cadherin structure by blocking
the ROS-induced stress kinase p38/27-kDa heat shock protein
signaling, which is known to mediate actin rearrangement (Ho
et al., 2006). Interestingly, prolactin, the molecule from which
vasoinhibins originate (Clapp et al., 2006), was recently shown to
prevent the decrease in brain-blood barrier permeability induced
by metamphetamine by maintaining the levels of claudin-5 and
occludin (Rosas-Hernandez et al., 2013).
In conclusion, vasoinhibins prevent the actions of BK on trans-
port through BRB and on the resistance of endothelium and
RPE. Vasoinhibin action is NO-dependent in both endothelial
and RPE cells and is ROS-dependent only in the RPE. Consistent
with these actions, vasoinhibins reduced the levels of ROS in
retinas of streptozotocin-diabetic rats, including the RPE. These
data extend the functions of BK in the retina, consolidate our
previous findings showing that vasoinhibins protect the BRB
under diabetic conditions, and provide novel molecular and cel-
lular insights into the mechanisms of vasoinhibin action in the
retina. Ultimately, because preclinical studies have shown that the
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administration of several inhibitors of kinin receptors (Phipps
et al., 2009; Clermont et al., 2011; Liu and Feener, 2013) and
of vasoinhibins (Ramirez et al., 2011) to diabetic rats amelio-
rates retinal vascular hyperpermeability and inflammation, this
study supports the use of vasoinhibins as therapeutic agents to
minimize BRB dysfunction.
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